Nanomedicine is a Hot Sector Expected to Grow by a Factor of Ten Times in the Near to Mid-Term and NanoViricides, Inc. (NYSE-American: NNVC) is a Leader in the Technology
“President and founder Anil R. Diwan, PhD. NNVC holds an exclusive, worldwide license to this technology for its antiviral drugs”
Good day everyone,
One of the newest frontiers in biopharma is nanomedicine. The application of nanotechnology for medical purposes is defined as the use of nanomaterials for diagnosis, monitoring, control, prevention, and treatment of diseases. I’ve been watching a small cap company that is a pioneer and is leading the way in this new and promising landscape.
NanoViricides, Inc. (NYSE-American: NNVC) is a company developing novel nanoviricide drug candidates for the eradication of viruses.
Current price $4.37 (at market close 10-8-21)
I urge to to read the recent corporate presentation to see the full potential here.
NNVC has a small share structure with 11.61M (est.) shares outstanding and 10.38M (est.) in the float. We note the shares are trading 50% off their March high of $8.71/share.
When I look at the company stock chart I note the shares have crossed their 50 DMA and 200 DMA of $4.17 and $4.21 respectively in a bullish manner. Furthermore, the support level for the company shares seems to have been increasing through this year and currently looks like $4.00 could be the latest support level. As the shares are coming off that support level and have crossed their 50 and 200 DMAs a bounce may be coming in the near term.
I wanted to know which other companies might be involved with this nascent sector. First, I found a dozen private start-ups with funding ranging from $20M to $500M. My search for public companies involved in nanomedicine only turned up big pharma companies with valuations in the billions.
NNVC could be your opportunity to buy shares in this rapidly growing sector (MarketWatch projects a 15.1% CAGR) at a low entry level.
NNVC is applying its nano technology to a broad range of viruses including influenza (both for out- patients and hospitalized patients), HIV, Ebola, Dengue/Marburg, Rabies, HSV Lesions, Herpes Keratitis, Hepatitis, Cold Sores, Shingles and Covid 19. Treatment for all these indications (except covid 19) are in pre-clinical studies preparing for an IND submission to the FDA. The company’s covid 19 development program has jumped to the front of the line.
NNVC and covid 19
Covid 19 has made many of us keenly aware of how viruses attack us, and the potential biopharma products used to combat them. The vaccines against covid have been quite effective but they are not a cure-all. Vaccinated people still get infected, just to a lesser degree, and many people could not or would not use the vaccines.
Antivirals have been in the biopharma arsenal for a long time to fight harmful viruses like RSV, Ebola, HIV, coronaviruses, and influenza and lowering the risk of spreading viruses to others. Antivirals work in several different ways to keep viruses out of the human body. Remdesivir, by Gilead Sciences is the only approved antiviral for covid 19, but it has its limitations because it metabolizes quickly inside the body and increasing the dosage can be toxic. NanoViricides created a complementary formulation to increase the effectiveness of remdesivir.
The NNVC product NV-CoV-2-R works by encapsulating remdesivir and preventing it from metabolizing too quickly. So far, the clinical trials show that NV-CoV-2-R extends the effectiveness of remdesivir. NV-CoV-2, the parent nanoviricide drug, works by attacking the virus particle outside cells while remdesivir is attacking the virus reproduction inside cells. By using the encapsulation platform, doctors should also be able to use a higher concentration of remdesivir.
NNVC product candidates are based on TheraCour® technology invented and developed by company president and founder Anil R. Diwan, PhD. NNVC holds an exclusive, worldwide license to this technology for its antiviral drugs. The technology is protected by two broad international patent applications that have resulted in several international patents. These patents cover compositions of matter, processes of manufacture, methods of use, and fields of use. Additional patent applications are anticipated, and the Company intends to patent each drug separately as well.
NNVC has one feature that makes it stand out from most development stage biopharma companies. They have their own manufacturing facility. It’s a multi-kilogram-scale c-GMP capable manufacturing facility for the drug substance as well as drug product, in Shelton, CT. This facility is 100% owned by the Company with no mortgage and is a major asset. This flexible, multi-product pilot plant can supply drug product for all their programs through human clinical trials. Further, it is capable of production for initial marketing, enabling early revenues upon drug approval, of about $100M-$500M per year.
About NanoViricides
NanoViricides, is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. They are developing clinical candidates for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Their other lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, the Company has several antiviral programs in various pre-clinical stages.
Stay tuned for more information about NNVC.
The Traders News Group
Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
https://tradersnewssource.com/cookie-policy-us/
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small acp stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty two thousand five hundred dollars cash via bank wire for our distributed opinions this week on nnvc. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.
